MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1 Terminated 46 enrolled University of Pennsylvania Alliance for Cancer Gene Therapy · collab National Cancer Institute (NCI) · collab OvaCure Fundation · collab Ovarian Cancer Alliance of Greater Cincinnati · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

Phase I study to establish safety and feasibility of intraperitoneally administered lentiviral transduced MOv19-BBz CAR T cells with or without cyclophosphamide + fludarabine as lymphodepleting chemotherapy

Timeline

Start: 2018-10-24
Primary completion: 2024-03-26
Completion: 2024-03-26

Outcome

Outcome not reported

Stopped (Enrollment): “This study was halted prematurely due to recruitment barriers”

Publications

Wang L, Cao Y, Ren Y, Zhang Y, Wang L. Different Immune Cells Modified With Chimeric Antigen Receptors Are Being Applied to Ovarian Cancer: Which Is the Most Effective? Cancer Med. 2026 May;15(5):e71897. doi: 10.1002/cam4.71897.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MOv19-BBz CAR T cells	Cell therapy	1e+06 unknown	—
Subject	MOv19-BBz CAR T cells	Cell therapy	1e+07 unknown	—
Subject	MOv19-BBz CAR T cells	Cell therapy	1e+08 cells	—